![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1665331
ÀÀ°í ºÐ¼®±â ½ÃÀå : ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)Coagulation Analyzers Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
¼¼°èÀÇ ÀÀ°í ºÐ¼®±â ½ÃÀåÀº 2024³â¿¡ 46¾ï ´Þ·¯¿¡ ´ÞÇß°í, 2025³âºÎÅÍ 2034³â±îÁö CAGR 6.1%·Î °·ÂÇÏ°Ô ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ÀÌ ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ´Â °ÍÀº Ç÷¿ìº´À̳ª Ç÷ÀüÁõ µîÀÇ Ç÷¾× Áúȯ À¯º´·üÀÇ »ó½Â¿¡ °¡¼¼ÇØ, ¾É±â ½¬¿î ¶óÀÌÇÁ ½ºÅ¸ÀÏÀ̳ª °í·ÉÈ, ºñ¸¸ÀÌ ¿øÀÎÀÌ µÇ´Â ½ÉÇ÷°ü ÇÕº´Áõ Áõ°¡ÀÔ´Ï´Ù. ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í Á¶±â Áø´Ü °Ë»ç°¡ º¸±ÞµÊ¿¡ µû¶ó ÀÇ·á ½Ã¼³¿¡¼ÀÇ ÀÀ°í ºÐ¼®±âÀÇ Ã¤¿ëÀÌ °¡¼Óȵǰí ÀÖ½À´Ï´Ù.
½ÃÀåÀº Á¦Ç° À¯Çüº°·Î ¼Ò¸ðǰ°ú Àåºñ·Î ±¸ºÐµÇ¸ç ¼Ò¸ðǰÀÌ ÁÖ·ù¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. CAGR 6.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ¼Ò¸ðǰ ºÎ¹®Àº 2034³â±îÁö 55¾ï ´Þ·¯¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áø´Ü¼¾ÅÍ¿Í °Ë»ç½ÇÀÌ ÀÏ»ó°ú Àü¹®ÀûÀÎ ÀÀ°í °Ë»ç¿¡ ÀÌ·¯ÇÑ Á¦Ç°À» ¸¹ÀÌ »ç¿ëÇϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ½Ã¾à ±â¼úÀÇ Áøº¸´Â ÀÚµ¿È ½Ã½ºÅÛ°úÀÇ ÀûÇÕ¼ºÀ» ³ôÀ̰í, °í¼º´É °Ë»ç ȯ°æ¿¡¼ÀÇ È¿À²°ú Á¤¹Ðµµ¸¦ Çâ»ó½Ã۰í, ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ ¿¬µµ | 2024³â |
¿¹Ãø ¿¬µµ | 2025-2034³â |
½ÃÀÛ ±Ý¾× | 46¾ï ´Þ·¯ |
¿¹Ãø ±Ý¾× | 82¾ï ´Þ·¯ |
CAGR | 6.1% |
°Ë»ç À¯Çüº°·Î´Â ÇÁ·ÎÆ®·Òºó ½Ã°£(PT) °Ë»ç, Ȱ¼ºÈ ºÎºÐ Æ®·Òº¸ÇÃ¶ó½ºÆ¾ ½Ã°£(aPTT) °Ë»ç, D ÀÌ·®Ã¼ °Ë»ç, ÇǺ긮³ë°Õ °Ë»ç ¹× ±âŸ °Ë»ç°¡ Æ÷ÇԵ˴ϴÙ. PT °Ë»ç´Â CAGR 6.6%¸¦ ´Þ¼ºÇßÀ¸¸ç 2034³â±îÁö 26¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ °Ë»ç´Â ÀÀ°í Àå¾Ö Áø´Ü, Ç×ÀÀ°í Ä¡·á ¸ð´ÏÅ͸µ, °£ ±â´É Æò°¡, ÃâÇ÷ ÀÌ»ó °ËÃâ¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÏ»óÀûÀÎ Áø´Ü ÀýÂ÷¿Í °í±Þ Áø´Ü ÀýÂ÷ ¸ðµÎ¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °ÍÀº ½ÃÀå ¼ºÀå¿¡ Å« ±â¿©¸¦ µÞ¹ÞħÇÕ´Ï´Ù.
¹Ì±¹ÀÇ ÀÀ°í ºÐ¼®±â ½ÃÀåÀº 2024³â¿¡ 15¾ï ´Þ·¯¿¡ À̸£·¶À¸¸ç, 2034³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 5.3%ÀÇ ¾ÈÁ¤ÀûÀÎ ¼ºÀåÀÌ ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹Àº ºÏ¹Ì ½ÃÀåÀ» ¼±µµÇϰí ÀÖÀ¸¸ç, ¼±Áø ÀÇ·á ÀÎÇÁ¶ó, ¾öû³ ÀÇ·áºñ, ½É¹æ¼¼µ¿ µî ¸¸¼ºÁúȯÀÇ ³ôÀº À¯º´·ü µîÀÇ ÇýÅÃÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Ç×ÀÀ°í ¿ä¹ýÀÇ È¿°úÀûÀÎ ¸ð´ÏÅ͸µÀÌ Á¡Á¡ ´õ Áß¿äÇØÁü¿¡ µû¶ó, ÀÀ°í °Ë»ç, ƯÈ÷ PT¿Í aPTT¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÓ»ó½Ç¿¡¼ ¿ÏÀü ÀÚµ¿È ½Ã½ºÅÛÀ» ÅëÇÕÇÏ¸é ¿öÅ©Ç÷οìÀÇ È¿À²¼ºÀ» ³ôÀÌ°í ´ë·® °Ë»çÀÇ ¿ä±¸¸¦ ÃæÁ·ÇÏ¸ç ±¹³» ½ÃÀåÀÇ ¿ìÀ§¸¦ °ÈÇϰí ÀÖ½À´Ï´Ù.
The Global Coagulation Analyzers Market reached USD 4.6 billion in 2024 and is poised to grow at a robust CAGR of 6.1% from 2025 to 2034. This growth is fueled by a rising prevalence of blood disorders such as hemophilia and thrombosis, alongside an increase in cardiovascular complications driven by sedentary lifestyles, aging populations, and obesity. As awareness of preventive healthcare expands and early diagnostic testing gains traction, the adoption of coagulation analyzers across healthcare facilities is accelerating.
The market is segmented by product type into consumables and instruments, with consumables expected to dominate. Projected to grow at a CAGR of 6.3%, the consumables segment is anticipated to generate USD 5.5 billion by 2034. The consistent demand for reagents, calibrators, and other essential consumables underpins this growth, as diagnostic centers and laboratories rely heavily on these products for routine and specialized coagulation testing. Advancements in reagent technology are enhancing compatibility with automated systems, driving efficiency and precision in high-throughput testing environments, further fueling demand.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $4.6 Billion |
Forecast Value | $8.2 Billion |
CAGR | 6.1% |
By test type, the market encompasses prothrombin time (PT) testing, activated partial thromboplastin time (aPTT) testing, D-dimer testing, fibrinogen testing, and other tests. PT testing is forecasted to achieve a CAGR of 6.6%, reaching USD 2.6 billion by 2034. This test is vital for diagnosing clotting disorders, monitoring anticoagulant therapies, assessing liver function, and detecting bleeding abnormalities. Its critical role in both routine and advanced diagnostic procedures underscores its significant contribution to market growth.
In the United States, the coagulation analyzers market reached USD 1.5 billion in 2024 and is projected to grow at a steady CAGR of 5.3% through 2034. The U.S. leads the North American market, benefiting from advanced healthcare infrastructure, substantial healthcare spending, and a high prevalence of chronic conditions like atrial fibrillation. The demand for coagulation tests, particularly PT and aPTT, continues to rise as effective monitoring of anticoagulant therapies becomes increasingly essential. Moreover, the integration of fully automated systems in clinical laboratories is enhancing workflow efficiency, meeting the needs of high-volume testing, and reinforcing the country's market dominance.